Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients
- PMID: 17294310
- DOI: 10.1007/s00464-006-9185-5
Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients
Abstract
Background: Non-alcoholic steatohepatitis (NASH) is a major cause of liver disease in morbidly obese patients. Clinical predictors of NASH remain elusive, as do molecular mechanisms of pathogenesis.
Methods: A series of 35 morbidly obese patients undergoing bariatric surgery had a liver biopsy performed for standard histologic analysis. In addition, RNA was obtained from liver tissue and analyzed for leptin receptor gene expression. Regression analysis was used to correlate clinical variables, including serum leptin levels and hepatic leptin receptor gene expression, with the presence of histologically confirmed NASH.
Results: Of the 35 subjects enrolled, 29% had steatosis only, 60% had NASH, and 11% had normal liver histology. Among the clinical variables studied, only diabetes mellitus was an independent predictor of NASH. There was a trend toward lower levels of mRNA encoding the long form of the leptin receptor in hepatic tissue from patients with NASH compared to those with steatosis only.
Conclusions: Diabetes mellitus is associated with an increased risk of NASH in obese patients. Downregulation of hepatic leptin receptor may play a role in the pathogenesis of NASH.
Similar articles
-
Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery.Chirurgia (Bucur). 2012 Nov-Dec;107(6):772-9. Chirurgia (Bucur). 2012. PMID: 23294957
-
Prevalence and predictors of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery: a Department of Defense experience.Am Surg. 2014 Jun;80(6):595-9. Am Surg. 2014. PMID: 24887798
-
Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.Obes Surg. 2006 Dec;16(12):1584-93. doi: 10.1381/096089206779319392. Obes Surg. 2006. PMID: 17217634
-
Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.Semin Liver Dis. 2008 Nov;28(4):407-26. doi: 10.1055/s-0028-1091985. Epub 2008 Oct 27. Semin Liver Dis. 2008. PMID: 18956297 Review.
-
Non-alcoholic steatohepatitis in morbidly obese patients.Clin Res Hepatol Gastroenterol. 2013 Feb;37(1):17-29. doi: 10.1016/j.clinre.2012.07.005. Epub 2013 Jan 21. Clin Res Hepatol Gastroenterol. 2013. PMID: 23347840 Review.
Cited by
-
Thyroid hormone-related regulation of gene expression in human fatty liver.J Clin Endocrinol Metab. 2009 Sep;94(9):3521-9. doi: 10.1210/jc.2009-0212. Epub 2009 Jun 23. J Clin Endocrinol Metab. 2009. PMID: 19549744 Free PMC article.
-
IGFBP-2 as a biomarker in NAFLD improves hepatic steatosis: an integrated bioinformatics and experimental study.Endocr Connect. 2021 Oct 13;10(10):1315-1325. doi: 10.1530/EC-21-0353. Endocr Connect. 2021. PMID: 34524971 Free PMC article.
-
GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells.World J Gastroenterol. 2014 Nov 14;20(42):15727-35. doi: 10.3748/wjg.v20.i42.15727. World J Gastroenterol. 2014. PMID: 25400456 Free PMC article.
-
Adiponectin but not leptin is involved in early hepatic disease in morbidly obese patients.Surg Endosc. 2010 Jul;24(7):1547-51. doi: 10.1007/s00464-009-0808-5. Epub 2009 Dec 30. Surg Endosc. 2010. PMID: 20041267 Clinical Trial.
-
Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.World J Gastroenterol. 2014 Aug 21;20(31):10851-63. doi: 10.3748/wjg.v20.i31.10851. World J Gastroenterol. 2014. PMID: 25152587 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous